ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 1943

The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis

Victoria Saferding1, Melanie Hofmann 2, Julia S. Brunner 2, Mihaela F. Militaru 2, Antonia Puchner 2, Silvia Hayer 2, Melanie Timmen 3, Richard Stange 3, Josef Smolen 2 and Stephan Blüml 4, 1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 2Medical University of Vienna, Vienna, Austria, 3University Hospital Muenster, Muenster, Germany, 4Medical University of Vienna, Vienna

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: miRNA, osteoblast, osteoclast and osteoporosis, wnt5a

Session Information

Date: Tuesday, November 12, 2019

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Micro RNAs (miRNAs) play a crucial role in the regulation of bone metabolism. MiR-146a, an important anti-inflammatory miRNA, was found to negatively impact osteogenesis and bone regeneration in vitro, by controlling the differentiation of mesenchymal stem cells. But to date the role of miR-146a in bone remodelling, its influence on bone stability and development of osteoporosis is not known.

Methods: Systemic bone, tibiae and femur, of wt, miR-146a-/- and miR- 146a-/- TRAF6+/- animals was assessed histologically and via µCT analysis, over a period of 3 to 18 months of age. Serum cytokine levels were analysed by Elisa. MRNA expression levels in bone were analysed by qPCR. To induce osteoporosis, ovariectomy (OVX) induced bone loss was performed.

Results: When we analysed bone volume of long bones histologically as well as with µCT analysis we detected significantly increased trabecular as well as cortical bone mass in miR-146a deficient compared to wt animals, starting at an age of 6 months. Dose reduction of TRAF6, a main target of miR-146a, using miR-146a-/- TRAF6+/- animals could not change the observed bone phenotype. Analysis of serum in aged miR-146a deficient animals displayed elevated activity of bone resorbing osteoclasts as amounts of CTX I in miR-146a-/- mice were significantly increased compared to wt animals. Q-PCR analysis of important osteoclast as well as osteoblast marker genes in bones ex vivo displayed elevated expression of signature molecules of both cell types in aged miR-146a deficient mice, suggesting a regulatory role of miR-146a in both cell types. Moreover, expression level of Wnt5a, a known target of miR-146a, influencing bone forming as well as bone resorbing cells, was strongly elevated in miR-146a-/- bones, possibly responsible for this deregulated bone growth. When we induced osteoporosis using the OVX disease model, histological analysis of long bones showed significant trabecular bone loss in ovariectomized wt mice. In contrast, we could not detect trabecular bone loss in ovariectomized miR-146a knock out animals, suggesting that loss of miR-146a deficiency protects bone loss induced by estrogen deficiency.

Conclusion: MiR-146a seems to control bone turnover and miR-146a deficient mice accrue bone over time. Moreover this miRNA has a negative influence on bone loss occurring during oestrogen loss induced osteoporosis. Therefore, miR-146a could be possibly used as a therapeutic target in the treatment of osteoporosis. 


Disclosure: V. Saferding, None; M. Hofmann, None; J. Brunner, None; M. Militaru, None; A. Puchner, None; S. Hayer, None; M. Timmen, None; R. Stange, None; J. Smolen, AbbVie, Amgen, Astra-Zeneca, Astro, Celgene Corporation, Celtrion, Eli Lilly, Glaxo, 8, AbbVie, Eli Lilly, Janssen, MSD, Pfizer, Roche, 2, ILTOO, Janssen, Medimmune, MSD, Novartis, Pfizer, Roche, Samsung, Sanofi, UCB, 8; S. Blüml, None.

To cite this abstract in AMA style:

Saferding V, Hofmann M, Brunner J, Militaru M, Puchner A, Hayer S, Timmen M, Stange R, Smolen J, Blüml S. The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-emerging-regulatory-function-of-microrna146a-in-bone-biology-and-osteoporosis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-emerging-regulatory-function-of-microrna146a-in-bone-biology-and-osteoporosis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology